Immune checkpoint inhibitor‐induced eosinophilic fasciitis: A pharmacovigilance and EADV Task force study
Journal of the European Academy of Dermatology and Venereology · 2026-10 · 40 (10) · 1702-1712
DOI: 10.1111/jdv.70512 ↗Abstract
Abstract Background With the widespread use of immune checkpoint inhibitors (ICI), rare cutaneous immune‐related adverse events (cirAEs), including ICI‐induced eosinophilic fasciitis (ICI‐EF), are increasingly encountered. However, data on its clinical presentation and optimal therapeutic approaches remain sparse. Objectives This study aimed to further characterize the clinical features and outcomes of ICI‐EF. Methods This retrospective observational study analysed clinical features, treatment strategies and outcomes of ICI‐EF cases from EADV Task Force‐affiliated dermatology departments, complemented by cases from the current available literature and two international pharmacovigilance databases. Patient demographics, clinical characteristics, diagnostics, treatment and follow‐up data were extracted from the medical records and databases. Results We present 121 ICI‐EF cases from the EADV Task Force ( n = 15), FPVD ( n = 21), VigiBase® ( n = 45) and the literature ( n = 40). The most prevalent underlying malignancy in all groups was melanoma (50%), with PD‐1 inhibitor monotherapy (81%) being the predominant offending drug class. The median time to ICI‐EF onset was 10 months (IQR 6.8–16.3; range < 1–36). Detailed clinical information was available for 76 of the 121 cases (63%), revealing a highly variable clinical presentation. Treatment primarily involved ICI discontinuation (83%) and systemic corticosteroids (80%), followed by methotrexate (41%), intravenous immunoglobulins (12%) and mycophenolate mofetil (13%), resulting in the partial or complete resolution of ICI‐EF symptoms (66%). Conclusions ICI‐EF is a rare heterogeneous cirAE with varying clinical features and significant morbidity. Early recognition and timely treatment are key to ensuring ICI continuation and preserve oncologic outcomes.
EUVIMED